首页 > 市场调查报告书 > 製药

神经疾病

帕金森氏症药物市场规模、份额和成长分析（按药物类别、给药途径、年龄层和地区划分）—产业预测（2026-2033 年）

市场调查报告书

商品编码

1901951

帕金森氏症药物市场规模、份额和成长分析（按药物类别、给药途径、年龄层和地区划分）—产业预测（2026-2033 年）

Parkinson's Disease Drug Market Size, Share, and Growth Analysis, By Drug Class (Decarboxylase Inhibitors, Dopamine Agonists), By Administration (Oral, Injection), By Age, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球帕金森氏症药物市场规模将达到 50.9 亿美元，到 2025 年将达到 56.3 亿美元，到 2033 年将达到 126 亿美元，在预测期（2026-2033 年）内，复合年增长率为 10.6%。

由于帕金森氏症这种神经系统疾病的盛行率不断上升，导致全球超过1000万人患病，并严重损害运动功能，因此帕金森氏症治疗市场正经历显着增长。多巴胺分泌减少会导致一系列严重的症状，从而催生了对有效治疗方法的需求。市场扩张的动力来自对联合治疗、创新长效药物以及促进神经移植的基因疗法等先进疗法的需求，并得到了政府资金的支持。此外，人口成长、医疗基础设施的改善、持续的研发投入以及不断增长的医疗支出等因素也为市场提供了持续的机会。同时，现有药物专利到期以及大量新兴治疗方法的涌现也为市场参与者带来了有利的前景。

全球帕金森氏症药物市场驱动因素

全球帕金森氏症药物市场的成长受到人口老化和神经系统疾病发病率上升的显着影响。随着帕金森氏症确诊患者人数的持续增加，对有效治疗方法方法的需求也随之增加。这种日益增长的医疗干预需求是推动市场发展的关键因素。此外，随着人们对该疾病认识的提高和药物研发的进步，满足帕金森氏症患者需求的迫切需求预计将进一步推动市场规模的显着扩张。

限制全球帕金森氏症药物市场的因素

帕金森氏症治疗成本的不断攀升预计将阻碍全球帕金森氏症治疗市场的成长。患者、其家庭和医疗保健系统面临的经济负担是一项重大挑战，限制了患者获得必要治疗的机会，并成为市场扩张的障碍。随着高昂成本的日益凸显，医疗资源整体压力不断增加，病患照护环境也更加复杂。因此，这一经济障碍仍然是限制市场成长的主要因素，并持续为帕金森氏症治疗领域的相关人员带来挑战。

全球帕金森氏症治疗市场趋势

全球帕金森氏症药物市场呈现显着上升趋势，这主要得益于研发投入的不断增加，以开发创新治疗方法。政府机构和私人企业的快速注资为专注于帕金森氏症新治疗方法研发的製药公司创造了充满活力的市场环境。这些努力不仅丰富了潜在药物的研发管线，也为先进治疗方法的开发铺平了道路，进一步提升了市场成长潜力。因此，持续研发有效帕金森氏症药物的努力预计将显着改变该市场的格局。

AbbVie Inc.（USA）
Novartis AG（Switzerland）
Teva Pharmaceutical Industries Ltd.（Israel）
UCB SA（Belgium）
GlaxoSmithKline plc（UK）
Merck & Co., Inc.（USA）
Boehringer Ingelheim（Germany）
Lundbeck A/S（Denmark）
Acadia Pharmaceuticals Inc.（USA）
Sun Pharmaceutical Industries Ltd.（India）
Amneal Pharmaceuticals, Inc.（USA）
Supernus Pharmaceuticals, Inc.（USA）
Kyowa Kirin Co., Ltd.（Japan）
Orion Corporation（Finland）
Neurocrine Biosciences, Inc.（USA）
Acorda Therapeutics, Inc.（USA）
Ipsen SA（France）
Luye Pharma Group（China）
NeuroDerm Ltd.（Israel）（acquired by Mitsubishi Tanabe Pharma）
Revance Therapeutics, Inc.（USA）

结论与建议

简介目录

Product Code: SQSG35I2024

Global Parkinson'S Disease Drug Market size was valued at USD 5.09 Billion in 2024 and is poised to grow from USD 5.63 Billion in 2025 to USD 12.6 Billion by 2033, growing at a CAGR of 10.6% during the forecast period (2026-2033).

The Parkinson's disease drug market is witnessing significant growth due to the increasing prevalence of this neurological condition, which affects over 10 million people globally and impairs movement. The decline in dopamine production leads to various debilitating symptoms, creating a demand for effective treatments. The market's expansion is driven by the need for combination therapies that enhance neural transplantation, innovative long-acting medications, and advancements like gene therapy, bolstered by government funding. Furthermore, factors such as a growing population, improved healthcare infrastructure, ongoing research and development, and rising healthcare expenditures position the market for continued opportunities. Additionally, the patent expirations of established drugs and a strong pipeline of emerging therapies present lucrative prospects for market players.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Parkinson'S Disease Drug market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Parkinson'S Disease Drug Market Segments Analysis

Global Parkinson'S Disease Drug Market is segmented by drug class, administration, age and region. Based on drug class, the market is segmented into decarboxylase inhibitors, dopamine agonists, COMT inhibitors, MAO-b inhibitors and others. Based on administration, the market is segmented into oral, injection and transdermal. Based on age, the market is segmented into < 50 years and > 50 years. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Parkinson'S Disease Drug Market

The growth of the global Parkinson's Disease drug market is significantly influenced by the escalating aging population and the rising incidence of neurological disorders. As the number of individuals diagnosed with Parkinson's disease continues to climb, there is a corresponding surge in the demand for effective treatments and therapies. This heightened need for medical interventions plays a crucial role in propelling the market forward. Furthermore, as awareness of the disease increases and advancements in drug development are made, the market is poised for substantial expansion, driven by the urgent requirement to address the needs of those affected by this debilitating condition.

Restraints in the Global Parkinson'S Disease Drug Market

The escalating costs associated with treating Parkinson's disease are expected to hinder the growth of the global market for Parkinson's disease drugs. The financial burden placed on patients, their families, and healthcare systems presents a significant challenge, limiting access to necessary treatments and creating barriers to market expansion. As these high expenses become more pronounced, they contribute to the overall strain on resources, further complicating the care landscape for those affected. Consequently, this financial hurdle remains a primary factor restraining market growth and poses ongoing challenges for stakeholders within the Parkinson's disease treatment sector.

Market Trends of the Global Parkinson'S Disease Drug Market

The Global Parkinson's Disease Drug market is witnessing a significant upward trend driven by heightened investment in research and development initiatives aimed at innovative treatment options. This surge in funding from both governmental bodies and private corporations is fostering a dynamic environment for pharmaceutical companies focused on crafting novel therapies for Parkinson's disease. These efforts are not only enhancing the pipeline of potential medications but are also paving the way for advanced treatment methodologies, thereby amplifying the market's growth potential. As a result, the ongoing commitment to developing effective Parkinson's disease drugs is set to significantly shape the landscape of this market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Parkinson's Disease Drug Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Decarboxylase Inhibitors
Dopamine Agonists
COMT Inhibitors
MAO-B Inhibitors
Others

Global Parkinson's Disease Drug Market Size by Administration & CAGR (2026-2033)

Market Overview
Oral
Injection
Transdermal

Global Parkinson's Disease Drug Market Size by Age & CAGR (2026-2033)

Market Overview
< 50 Years
>50 Years

Global Parkinson's Disease Drug Market Size & CAGR (2026-2033)

North America (Drug Class, Administration, Age)
- US
- Canada
Europe (Drug Class, Administration, Age)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Administration, Age)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Administration, Age)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Administration, Age)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acadia Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amneal Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Supernus Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orion Corporation (Finland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neurocrine Biosciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acorda Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen S.A. (France)
- Company OvervSiew
- Business Segment Overview
- Financial Updates
- Key Developments
Luye Pharma Group (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeuroDerm Ltd. (Israel) (acquired by Mitsubishi Tanabe Pharma)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Revance Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments